Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Jul 15, 2014; 6(7): 211-224
Published online Jul 15, 2014. doi: 10.4251/wjgo.v6.i7.211
Published online Jul 15, 2014. doi: 10.4251/wjgo.v6.i7.211
Table 1 Selected phase 3 clinical trials involving anti-angiogenic drugs in combination with conventional chemotherapy
Ref. | Drug and study name | Study description | No. of patients | Comparison | Median OS (mo) | Median TTP/PFS (mo) | ORR | 1-yr survival |
Bevacizumab (B) | ||||||||
Hurwitz et al[8] 2004 | AVF2107g trial | RCT, 1st line | 813 (ITT) | IFL + B vs IFL | 20.3 vs 15.6 | 10.6 vs 6.2 | 45% vs 35% | 74% vs 63% |
Fuchs et al[10] 2007 | BICC-C trial | RCT, 1st line | 117 (2nd period) | FOLFIRI + B vs mIFL + B | 28 vs 19 | 11 vs 8 | 58% vs 53% | 87% vs 61% |
Giantonio et al[12] 2007 | ECOG 3200 trial | RCT, 2nd line post irinotecan 1st line | 820 (ITT) | FOLFOX-4 + B vs FOLFOX-4 vs B alone | 12.9 vs 10.8 vs 10.2 | 7.3 vs 4.7 vs 2.7 | 23% vs 8.6% vs 3.3% | 56% vs 43% vs 44% |
Saltz et al[13] 2008 | NO16966 trial | RCT, phase 3, 1st line, factorial 2 x 2 | 1401 | FOLFOX-4 or XELOX + B vs FOLFOX-4 or XELOX | 21.3 vs 19.9 | 9.4 vs 8.0 | 47% vs 49% | Not reported |
Tebbutt et al[17] 2010 | MAX trial | RCT, open label, 1st line | 471 | Cape alone vs Cape + B vs Cape + B + mitomycin | 18.9 18.9 vs 16.4 | 5.7 vs 8.5 vs 8.4 | 30% vs 38% vs 46% | Not reported |
Cunningham et al[18] 2013 | AVEX trial | RCT, elder population, 1st line | 280 | Cape alone vs Cape + B | 20.7 vs 16.8 | 9.1 vs 5.1 | 19% vs 10% | 74% vs 44% |
Falcone et al[21] 2013 | TRIBE trial | RCT, 1st line | 508 | FOLFOXIRI-B vs FOLFIRI-B | 31.0 vs 25.8 | 12.1 vs 9.7 | 65% vs 53% | Not reported |
Bennouna et al[66] 2013 | ML 18147 | RCT, open label, 2nd line post chemo + B | 409 | 2nd line chemotherapy + B vs 2nd line chemotherapy | 11.2 vs 9.8 | 5.7 vs 4.1 | 5.5% vs 4% | Not reported (approximately 50% vs 40%) |
Ziv-Aflibercept | ||||||||
Van Cutsem et al[29] 2012 | VELOUR trial | RCT, 2nd line post oxaliplatin and/or bevacizumab 1st line | 1226 | FOLFIRI + aflibercept vs FOLFIRI + placebo | 13.5 vs 12.0 | 6.9 vs 4.7 | 20% vs 11% | 56% vs 50% |
- Citation: Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224
- URL: https://www.wjgnet.com/1948-5204/full/v6/i7/211.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v6.i7.211